Houston voices

Rice University professor and startup founder talks advocating for change and strategy

Robyn O'Brien joined the Liu Idea Lab of Innovation and Entrepreneurship to discuss how she's found success in advocating for change with her latest startup. Photo via robynobrien.com

Robyn O'Brien, co-founder of rePlant Capital and Rice adjunct professor, joined the Liu Idea Lab for Innovation and Entrepreneurship for the first virtual Ladies who LaUNCH. RePlant Capital is working with food industry players to invest in resilient and sustainable agricultural practices. She continues working toward her goal to "make clean and safe food affordable and accessible to anyone who wants it."

After receiving an MBA from Rice, O'Brien found herself thrust into the world of food as a financial analyst. Years later when her one-year old child had a severe allergic reaction, Robyn's previous work experience in the food industry suddenly became much more personal. She dug into the data and unearthed injustice hidden in the US food industry, resulting in her book, The Unhealthy Truth. She brought to light some shocking realities about the rise in food related allergies in the US and the double standards of food quality in the US versus other international markets. Companies were selling one product in Europe with wholesome ingredients, while "the same" product in the US was made of artificial ingredients and chemicals.

As a rebel-rousing public figure, Robyn has received her fair share of push back, but she has come out of the storm more resilient and compassionate because of it. Over the course of her hour-long talk, Robyn shared some of the ways that she has been able to advocate for change, as a mom up against industry giants and those with power to silence her. A few of the strategies she has found to be fool proof are:

1. Although her story about the US food market is quite shocking, O'Brien explained that she has lead and advocated from a place of love, not fear. O'Brien reminds us, "The reason we're hurting… is because we love." Whether she's communicating with a national audience or working on a team, Robyn has found success by turning to empathy and encourages us to do the same. Even internally, when there is discourse in her team, she says, "Start with compassion."

2. Lead with data. Despite how personal the issue felt to Robyn and the anger we are justified in feeling about this issue, Robyn continually relies on the data to do the convincing as opposed to an emotional response. "Don't exaggerate… data will tell it's own story." She encourages us to do our homework, know our facts, and walk into meetings confidently.

3. You have to exercise courage daily. ""Courage is a muscle. The more you use it, the stronger it gets." And when your internal meter senses something is misaligned, listen to it. There is room for change in departments and large organizations and it takes courage to address these issues. But it also takes courage to recognize the "gut check" and acknowledge when the misalignment is too great, and to walk away.

O'Brien is a great example of sticking to your guns, even when you're up against a global industry. Now, I leave you with the challenge of taking smaller steps – plant seeds of change where you are and advocate for individuals in need.

------

This article originally appeared on Liu Idea Lab for Innovation & Entrepreneurship's blog.

Trending News

Building Houston

 
 

BiVACOR has received fresh funding from its investors to further develop its artificial heart. Photo courtesy of BiVACOR

A Houston medical device company that is developing an artificial heart announced it has received investment funding to the tune of $18 million.

BiVACOR's investment round was led by Boston-based Cormorant Asset Management and Australia's OneVentures's Healthcare Fund III. According to the company, the funding will be deployed to continue research and development, hiring executives, and support the path to first in human trials.

“We are extremely grateful for the ongoing support from our core investors," says Thomas Vassiliades, who was named CEO of BiVACOR last year, in a news release. "This additional commitment further validates our technology and the need for improved options to treat end-stage biventricular heart failure.

“With this financing, we will be able to double the size of our organization and add key positions from the C-suite to research and development. We are well positioned to advance our preclinical activities and aim to conduct our First in Human early feasibility study planned for the end of the year,” he continues.

Billed as the first long-term treatment for patients with severe biventricular heart failure, the BiVACOR Total Artificial Heart is an implantable artificial heart that utilizes rotary blood pump technology. This technology includes magnetic levitation and is a "durable, reliable, and biocompatible heart replacement," per the company's release. It's about the size of a fist and can be used in a wide range of patients including some children and women and up to adult males.

“Under the leadership of its expert management team, the company has developed a credible strategy for growth as they march toward first in human studies,” says Jeannie Joughin, board chair and principal at One Ventures, in the release. “There is a huge gap in care for patients waiting for a heart transplant, and we are confident that BiVACOR will continue to execute its strategy to swiftly get the Total Artificial Heart into the patients who need it most.”

The company raised its $22 million series B round in early 2021, which was also led by Cormorant Asset Management and OneVentures. To date, BiVACOR has raised $60 million.

“BiVACOR continues to execute on its strategy, and there was no question that we would jump in to lead this funding,” says Bihua Chen, CEO and founder of Cormorant Asset Management. “We are impressed by BiVACOR’s world-class team and continued dedication to push the technology in the clinic. We’re excited to support their growth and vision to transform the treatment of biventricular heart failure with the world’s first fully MAGLEV total artificial heart.”

Founded in 2008, BiVACOR maintains offices in Cerritos, California, and Brisbane, Australia. The company is affiliated with Houston's Texas Heart Institute, where the world's first artificial heart was implanted. BiVACOR's headquarters is at the Texas Medical Center complex.

Trending News